A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ribociclib (Primary) ; Trametinib (Primary)
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Pancreatic cancer; Rectal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Novartis; Novartis Pharmaceuticals

21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress.
03 Jul 2020 Status changed from completed to discontinued.
13 Feb 2020 Status changed from discontinued to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com